ArticleScientific reports2025
Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut‑bone metabolites: SCFAs, polyamines and microbial metabolomics in osteoporosis risk and therapy (Review).International journal of molecular medicine · 2026Review
- Metabolic reprogramming in cancer: signaling pathways and therapeutic targets.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to identify and validate prognostic genes associated with polyamine metabolism-related genes (PMRGs) in hepatocellular carcinoma (HCC), offering potential novel therapeutic targets and strategies. The HCC-related datasets and 19 PMRGs were included in this study. Prognostic genes were screened out through differential expression analysis, univariate and multivariate Cox regression analysis. Subsequently, the construction of the risk model and nomogram, as well as functional enrichment and immune infiltration analysis were carried out. Ultimately, prognostic gene expression was further validated by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme linked immunosorbent assay (ELISA). SMOX, SRM, and SAT1 were identified as prognostic genes. risk score and stage were investigated as independent prognostic factors to construct nomogram. Moreover, the drug metabolism cytochrome p450 pathway was found had a significantly enriched in different risk groups. After that, 11 immune cells differed significantly across risk groups, with Eosinophi having the highest positive/negative correlation with SAT1/SRM, respectively. Finally, SMOX and SRM were highly expressed in the HCC group, while SAT1 showed the opposite pattern. The three genes linked to PMRGs, were identified as prognostic genes for constructing risk models, which may provide a basis for understanding HCC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.